Unit­ed ax­es PAH pro­gram Trevyent, once bought for cheap in ac­qui­si­tion of a ri­val, af­ter FDA feed­back

5 years ago
FDA+

Swiss CD­MO Celonic finds a home at No­var­tis' Stein hub, plans to add 250 new jobs cen­tered on next-gen drugs

5 years ago
Outsourcing
Cell/Gene Tx

The 2021 top 100 bio­phar­ma in­vestors: As the pan­dem­ic hit and IPOs boomed, VCs swung in­to ac­tion like nev­er be­fore

5 years ago
Financing
Special

Eli Lil­ly claims suc­cess in a new JAK in­di­ca­tion: hair loss

5 years ago
R&D

Fresh off $1B+ Mer­ck deal, Janux locks down first pri­vate fundraise for its T cell en­gagers

5 years ago
Financing

A Jen­nifer Doud­na-launched up­start nabs $115M for off-the-shelf CAR-Ts

5 years ago
Financing

Thank you, next: Take­da hands Ovid $196M cash to rein back in Phase III-ready seizure drug, re­viv­ing bat­tered stock

5 years ago
Deals

Covid-19 roundup: Mer­ck pre­pares new study on their $425M Covid drug; CO­V­AX be­gins roll­out but huge dis­par­i­ties still ...

5 years ago
Coronavirus

As al­lo­gene­ic cell ther­a­py ap­proach­es flour­ish, Cen­tu­ry loads up $160M to scale iP­SC plat­form for CAR-T, CAR-NK

5 years ago
Financing
Cell/Gene Tx

Khosla joins bet on un­con­ven­tion­al start­up look­ing to send drug de­liv­er­ing ro­bots in­to the brain

5 years ago
Startups

One of Are­na's top drugs flops in a PhI­Ib study for IBS pain. But re­searchers tease out a pos­si­ble path for­ward as ...

5 years ago
R&D

With stars aligned and cash in re­serve, Bob Nelsen's Re­silience plans a makeover at 2 new fa­cil­i­ty ad­di­tions to its ...

5 years ago
Manufacturing

'N­ev­er been more ur­gent:' Scynex­is looks to tack­le su­per­bug cri­sis with late-stage read­out for an­ti­fun­gal hope­ful

5 years ago
R&D

A spot­light schiz­o­phre­nia drug in Neu­ro­crine's $2B Take­da deal flunks its first ma­jor test. But it's not giv­ing up ...

5 years ago
R&D

Mesoblast gets a $110M life­line from Surg­Cen­ter De­vel­op­ment; uniQure still un­sure if gene ther­a­py spurred can­cer ...

5 years ago
News Briefing

Af­ter bail­ing on Covid-19 vac­cines, Mer­ck will team up with J&J to pro­duce its shot as part of un­usu­al Big Phar­ma ...

5 years ago
Coronavirus
Manufacturing

Ab­b­Vie tees up a biotech buy­out af­ter siz­ing up their Parkin­son's drug spun out of Ke­van Shokat's lab

5 years ago
Deals

The next big biotech su­per­star? Paul Sekhri has some thoughts on that

5 years ago
Financing

A 'love sto­ry': WuXi AppTec wraps UK-based CRO in­to its cell and gene ther­a­py unit

5 years ago
Deals
Outsourcing

Fi­bro­Gen shares skid low­er as a sur­prise ad­comm rais­es risks on roxa OK

5 years ago
FDA+

How we are stay­ing con­nect­ed when we’re apart

5 years ago
Biotech Voices

Covid-19 roundup: As­traZeneca ships first CO­V­AX dos­es as Cana­da rec­om­mends against 65+ use; In­ovio, still stuck in ...

5 years ago
Coronavirus

In­tro­duc­ing End­points FDA+, our new pre­mi­um week­ly reg­u­la­to­ry news re­port led by Zachary Bren­nan

5 years ago
Publisher's note

Mer­ck pulls Keytru­da in SCLC af­ter ac­cel­er­at­ed nod. Is the FDA get­ting tough on drug­mak­ers that don't hit their ...

5 years ago
Pharma
FDA+
First page Previous page 727728729730731732733 Next page Last page
A service from the Financial Times